All In Biotech

Drug Trial Radar · NCT04697628

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Last checked: Nov 20, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 502 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

502

Actual

Start

Feb 22, 2021

Primary completion

Jul 24, 2023

Study completion Jan 15, 2026

Sponsor

Sponsor type
Industry
Collaborators
Genmab
First posted
Jan 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent). Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.

Conditions

  • Cervical Cancer

Interventions

  • tisotumab vedotinDrug

    2.0 mg/kg every 3 weeks (Q3W)

  • topotecanDrug

    1 or 1.25 mg/m2 intravenous (IV) on Days 1 to 5, every 21 days

  • vinorelbineDrug

    30 mg/m2 IV on Days 1 and 8, every 21 days

  • gemcitabineDrug

    1000 mg/m2 IV on Days 1 and 8, every 21 days

  • irinotecanDrug

    100 or 125 mg/m2 IV weekly for 28 days, every 42 days

  • pemetrexedDrug

    500 mg/m2 IV on Day 1, every 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)

Locations

211 sites in 25 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC - HAL

    Glendale, Arizona

  • Arizona Oncology Associates P.C. - NAHOA

    Phoenix, Arizona

  • Arizona Oncology Associates, PC - HAL

    Phoenix, Arizona

  • Arizona Oncology Associates, PC - HAL

    Scottsdale, Arizona

  • Arizona Oncology Associates, PC - HAL

    Tempe, Arizona

  • University of California Irvine Health

    Irvine, California

  • UC Irvine Health (Investigator Site File Location)

    Orange, California

  • University of California Irvine Health

    Orange, California

  • Olive View - UCLA Medical Center

    Sylmar, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Broward Health Medical Center

    Fort Lauderdale, Florida

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia

  • Northwestern Medical Group

    Chicago, Illinois

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Norton Cancer Institute, Downtown

    Louisville, Kentucky

  • Norton Hospital

    Louisville, Kentucky

  • Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD

    Louisville, Kentucky

  • Norton Cancer Institute, St. Matthews Campus

    Louisville, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • Norton Women's & Children's Hospital

    Louisville, Kentucky

  • Willis-Knighton Cancer Center Infusion Center

    Shreveport, Louisiana

  • Willis-Knighton Physician Network/ Hematology-Oncology Associates

    Shreveport, Louisiana

  • Willis-Knighton Physician Network/WK Gynecologic Oncology Associates

    Shreveport, Louisiana

  • Willis-Knighton Physician Network/WK Gynecologic Oncology Associates

    Shreveport, Louisiana

  • Minnesota Oncology Hematology PA

    Coon Rapids, Minnesota

  • Minnesota Oncology Hematology, P.A

    Coon Rapids, Minnesota

  • Minnesota Oncology Hematology, P.A

    Edina, Minnesota

  • Minnesota Oncology Hematology, P.A

    Maplewood, Minnesota

  • Minnesota Oncology Hematology, P.A

    Minneapolis, Minnesota

  • Minnesota Oncology Hematology, P.A

    Saint Paul, Minnesota

  • St. Dominic- Jackson Memorial Hospital Pharmacy Attn: Richard Wakefield

    Jackson, Mississippi

  • Washington University School of Medicine- Obstetrics & Gynecology [Academic Offices]

    St Louis, Missouri

  • Washington University School of Medicine [Patient Clinics]

    St Louis, Missouri

  • Washington University School of Medicine-Obstetrics & Gynecology

    St Louis, Missouri

  • NewYork Presbyterian - Brooklyn Methodist Hospital

    Brooklyn, New York

  • NewYork Presbyterian - Queens

    Flushing, New York

  • NewYork Presbyterian - Queens

    Forest Hills, New York

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone.

    New York, New York

  • NYU Langone Medical Center

    New York, New York

  • Cleveland Clinic Taussig Cancer Center Investigational Pharmacy

    Cleveland, Ohio

Showing 40 of 211 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.